Latest News

  • FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder Read More
  • Trading in Alkermes Ordinary Shares Halted Today Read More
  • Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 Read More
  • Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Response to Current Events

Response to Current Events
Response to Current Events Read Our Statement